Enzymotec Ltd (ENZY) 8.00 $ENZY
Tracking John Paulson's Paulson & Company Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Thu Nov 20, 12:49AM CST
RKT: 57.20 (-1.69), KOG: 6.56 (-0.39), MEAS: 86.00 (+0.01), HHC: 127.30 (-3.11), AET: 87.30 (-0.82), DLPH: 69.77 (-1.39), DLTR: 68.14 (+0.38), AEM: 24.24 (-0.29), AUXL: 33.11 (-0.72), DG: 69.80 (+0.65), ABBV: 65.27 (-1.76), DXM: 9.47 (-0.22), MNK: 94.72 (-0.36), ATHL: 58.40 (unch), NCQ: 0.57 (+0.01), COV: 100.49 (-1.36), AU: 8.21 (-0.06), MYL: 53.32 (-1.39), IAG: 2.57 (+0.06), FDO: 79.25 (-0.23), MGM: 20.18 (-0.36), GNW: 7.92 (-0.32), HIG: 40.39 (-0.78), NG: 2.68 (+0.02), EQIX: 226.33 (-5.92), HSH: 62.96 (unch), OAS: 12.33 (+1.28), PETM: 77.67 (-0.77), ACT: 259.00 (-4.00), MDT: 72.52 (-1.25), BPOP: 32.07 (-0.49), ENZY: 8.00 (+0.21), FCX: 21.78 (-1.20), GFI: 4.29 (-0.17), CZR: 12.83 (-2.03), CVC: 19.74 (-0.30), CIE: 7.82 (+0.19), CACQ: 9.03 (-0.28), AGN: 208.47 (-2.67), ECA: 12.19 (-0.39), FCH: 10.42 (-0.17), R: 87.71 (-0.80), DTV: 83.47 (-0.43), KMDA: 3.51 (-0.02), ANV: 0.74 (-0.04), MOVE: 20.95 (-0.03), BAC: 17.13 (-0.34), GRFS: 31.95 (-0.79), POST: 41.39 (-0.81), HCA: 72.94 (-0.62), RDN: 16.68 (-0.23), BEE: 13.12 (+0.03), CPWR: 10.34 (unch), GLD: 117.41 (-0.28), RLGY: 42.88 (-0.88), MTG: 8.98 (-0.12), HMHC: 19.87 (-0.43), CMCSA: 55.35 (-0.55), CBS: 53.48 (+0.99), BABA: 105.11 (+0.14)
Enzymotec Ltd. (ENZY) in Focus: Stock Rallies 15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 7:44AM CST
Enzymotec Ltd. (ENZY) was a big mover last session, as the company saw its shares surge 15% on the day.
ICUI: 80.95 (-1.04), ABAX: 57.20 (+0.61), GWPH: 72.41 (+1.18), ENZY: 8.00 (+0.21)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:47AM CST
CADC: 5.36 (+0.05), ANV: 0.74 (-0.04), BONE: 2.83 (-0.01), WLH: 18.55 (-0.43), CLDX: 18.03 (-0.16), ENZY: 8.00 (+0.21), TGEN: 5.26 (-0.14), CHOP: 1.88 (+0.15), MSBF: 10.20 (+0.05), NVGN: 1.64 (-0.06), DWA: 21.75 (+0.04), WHX: 1.95 (-0.13), VYFC: 19.75 (-0.01), VGGL: 3.30 (-0.09), SNSS: 2.26 (unch), DNR: 6.40 (-0.22), MOBI: 4.16 (-0.07), VPCO: 1.31 (+0.04), FOLD: 8.15 (+0.18), ATEA: 1.26 (-0.07)
Enzymotec's (ENZY) CEO Dr. Ariel Katz on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 12:50PM CST
ENZY: 8.00 (+0.21)
Enzymotec beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:34AM CST
ENZY: 8.00 (+0.21)
Enzymotec Ltd. Reports Third Quarter 2014 Unaudited Financial Results
GlobeNewswire - Thu Nov 13, 6:30AM CST
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today reported its financial results for the third quarter ended September 30, 2014.
ENZY: 8.00 (+0.21)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:30PM CST
KSS: 57.27 (+0.37), VTNR: 3.21 (-0.03), TYC: 41.55 (-0.63), SPH: 42.55 (-0.91), FLY: 13.20 (-0.61), ENZY: 8.00 (+0.21), RWLK: 21.22 (-0.28), WMT: 83.81 (-0.02), RSTI: 29.03 (-0.57), SBH: 30.85 (-0.27), HP: 60.34 (-1.33), GIB: 34.92 (-0.88), TDG: 192.06 (-1.08), CLFD: 11.92 (+0.21), HIMX: 7.97 (-0.02), VIAB: 72.96 (-0.01), MMS: 51.28 (-0.80)
Enzymotec Ltd. Initiates Clinical Study of Vayarin(R) in Adult ADHD
GlobeNewswire - Tue Nov 11, 7:38AM CST
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer, and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, today announced the initiation of a clinical study to evaluate the efficacy of Vayarin(R) in adults with Attention Deficit Hyperactivity Disorder, or ADHD.
ENZY: 8.00 (+0.21)
Enzymotec to Report Third Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Thu Oct 30, 7:30AM CDT
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today announced that the Company will release financial results for the third quarter ended September 30, 2014 on Thursday, November 13, 2014, before the market opens. Following the release, Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer will host a conference call to review the financial results.
ENZY: 8.00 (+0.21)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Involving Enzymotec Ltd. and a Lead Plaintiff Deadline of November 4, 2014 -- ENZY
GlobeNewswire - Wed Oct 29, 11:17AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Enzymotec Ltd. ("Enzymotec" or the "Company"
(Nasdaq:ENZY) common stock pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or investors who purchased shares on the open market between September 27, 2013 and August 4, 2014.
ENZY: 8.00 (+0.21)
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Enzymotec Ltd.
Business Wire - Wed Oct 29, 9:30AM CDT
Glancy Binkow & Goldberg LLP reminds investors of Enzymotec Ltd. ("Enzymotec" or the "Company" (NASDAQ:ENZY) that all purchasers of the Company's securities pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period" , have until November 4, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
ENZY: 8.00 (+0.21)
NOV. 4th DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Enzymotec Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of November 4, 2014
Business Wire - Mon Oct 27, 2:45PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Enzymotec Ltd. ("Enzymotec" or the "Company" (Nasdaq:ENZY) common stock pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or investors who purchased shares on the open market between September 27, 2013 and August 4, 2014.
ENZY: 8.00 (+0.21)
Which Stocks Hurt Billionaire Portfolios the Most in 2014?
at The Street - Mon Oct 27, 7:48AM CDT
See the stocks that have performed the worst for 19 billionaires who made their money investing.
BID: 38.82 (+0.06), CBI: 39.14 (-1.17), MDR: 2.46 (-0.17), DLIA: 0.01 (unch), EOPN: 7.57 (-0.11), PGEM: 12.18 (-0.35), ENZY: 8.00 (+0.21), GNC: 42.58 (-0.03), AMCC: 5.87 (+0.03), HHC: 127.30 (-3.11), LL: 58.88 (-0.35), VLTC: 0.82 (-0.07), CZR: 12.83 (-2.03), SNSS: 2.26 (unch), TWER: 1.62 (+0.05), SHOS: 12.00 (-0.04), DRYS: 0.86 (-0.05), CREE: 30.16 (-0.17)
ENZYMOTEC SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Enzymotec Ltd. -- ENZY
GlobeNewswire - Sat Oct 25, 4:49PM CDT
Kahn Swick & Foti, LLC ("KSF" and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 4, 2014 to file lead plaintiff applications in a securities class action lawsuit against Enzymotec Ltd. (Nasdaq:ENZY), if they purchased the Company's securities in connection with the Company's initial public offering ("IPO" on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period" . This action is pending in the United States District Court for the District of New Jersey.
ENZY: 8.00 (+0.21)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Enzymotec Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of November 4, 2014
Business Wire - Tue Oct 21, 11:52AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Enzymotec Ltd. ("Enzymotec" or the "Company" (Nasdaq:ENZY) common stock pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or investors who purchased shares on the open market between September 27, 2013 and August 4, 2014.
ENZY: 8.00 (+0.21)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against Enzymotec Ltd.
Business Wire - Thu Oct 16, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that purchasers of the securities of Enzymotec Ltd. ("Enzymotec" or the "Company" (NASDAQ:ENZY) pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period" , have until November 4, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
ENZY: 8.00 (+0.21)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Enzymotec Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of November 4, 2014 -- ENZY
PR Newswire - Mon Oct 06, 1:33PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Enzymotec Ltd. ("Enzymotec" or the "Company" (Nasdaq: ENZY) common stock pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or investors who purchased shares on the open market between September 27, 2013 and August 4, 2014.
ENZY: 8.00 (+0.21)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Enzymotec Ltd. to Contact Brower Piven Before the November 4, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- ENZY
GlobeNewswire - Sat Oct 04, 7:00AM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Enzymotec Ltd. ("Enzymotec" or the "Company" (Nasdaq:ENZY) securities pursuant and/or traceable to the Company's Registration Statement and Prospectus ("Offering Documents" issued in connection with the Company's initial public offering on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period" .
ENZY: 8.00 (+0.21)
ENZYMOTEC SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Enzymotec Ltd.
Business Wire - Fri Oct 03, 5:22PM CDT
Kahn Swick & Foti, LLC ("KSF" and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 4, 2014 to file lead plaintiff applications in a securities class action lawsuit against Enzymotec Ltd. (Nasdaq: ENZY), if they purchased the Company's securities in connection with the Company's initial public offering ("IPO" on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period" . This action is pending in the United States District Court for the District of New Jersey.
ENZY: 8.00 (+0.21)
EQUITY ALERT: The Rosen Law Firm Reminds Enzymotec Ltd. Investors of Important Class Action Deadline -- ENZY
GlobeNewswire - Thu Oct 02, 1:13PM CDT
The Rosen Law Firm reminds purchasers of Enzymotec Ltd. securities (Nasdaq:ENZY) during the period from September 27, 2013 through August 4, 2014, of the important November 4, 2014 class action deadline.
ENZY: 8.00 (+0.21)
Tracking John Paulson's Paulson & Company Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Thu Nov 20, 12:49AM CST
RKT: 57.20 (-1.69), KOG: 6.56 (-0.39), MEAS: 86.00 (+0.01), HHC: 127.30 (-3.11), AET: 87.30 (-0.82), DLPH: 69.77 (-1.39), DLTR: 68.14 (+0.38), AEM: 24.24 (-0.29), AUXL: 33.11 (-0.72), DG: 69.80 (+0.65), ABBV: 65.27 (-1.76), DXM: 9.47 (-0.22), MNK: 94.72 (-0.36), ATHL: 58.40 (unch), NCQ: 0.57 (+0.01), COV: 100.49 (-1.36), AU: 8.21 (-0.06), MYL: 53.32 (-1.39), IAG: 2.57 (+0.06), FDO: 79.25 (-0.23), MGM: 20.18 (-0.36), GNW: 7.92 (-0.32), HIG: 40.39 (-0.78), NG: 2.68 (+0.02), EQIX: 226.33 (-5.92), HSH: 62.96 (unch), OAS: 12.33 (+1.28), PETM: 77.67 (-0.77), ACT: 259.00 (-4.00), MDT: 72.52 (-1.25), BPOP: 32.07 (-0.49), ENZY: 8.00 (+0.21), FCX: 21.78 (-1.20), GFI: 4.29 (-0.17), CZR: 12.83 (-2.03), CVC: 19.74 (-0.30), CIE: 7.82 (+0.19), CACQ: 9.03 (-0.28), AGN: 208.47 (-2.67), ECA: 12.19 (-0.39), FCH: 10.42 (-0.17), R: 87.71 (-0.80), DTV: 83.47 (-0.43), KMDA: 3.51 (-0.02), ANV: 0.74 (-0.04), MOVE: 20.95 (-0.03), BAC: 17.13 (-0.34), GRFS: 31.95 (-0.79), POST: 41.39 (-0.81), HCA: 72.94 (-0.62), RDN: 16.68 (-0.23), BEE: 13.12 (+0.03), CPWR: 10.34 (unch), GLD: 117.41 (-0.28), RLGY: 42.88 (-0.88), MTG: 8.98 (-0.12), HMHC: 19.87 (-0.43), CMCSA: 55.35 (-0.55), CBS: 53.48 (+0.99), BABA: 105.11 (+0.14)
Enzymotec Ltd. (ENZY) in Focus: Stock Rallies 15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 7:44AM CST
Enzymotec Ltd. (ENZY) was a big mover last session, as the company saw its shares surge 15% on the day.
ICUI: 80.95 (-1.04), ABAX: 57.20 (+0.61), GWPH: 72.41 (+1.18), ENZY: 8.00 (+0.21)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:47AM CST
CADC: 5.36 (+0.05), ANV: 0.74 (-0.04), BONE: 2.83 (-0.01), WLH: 18.55 (-0.43), CLDX: 18.03 (-0.16), ENZY: 8.00 (+0.21), TGEN: 5.26 (-0.14), CHOP: 1.88 (+0.15), MSBF: 10.20 (+0.05), NVGN: 1.64 (-0.06), DWA: 21.75 (+0.04), WHX: 1.95 (-0.13), VYFC: 19.75 (-0.01), VGGL: 3.30 (-0.09), SNSS: 2.26 (unch), DNR: 6.40 (-0.22), MOBI: 4.16 (-0.07), VPCO: 1.31 (+0.04), FOLD: 8.15 (+0.18), ATEA: 1.26 (-0.07)
Enzymotec's (ENZY) CEO Dr. Ariel Katz on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 12:50PM CST
ENZY: 8.00 (+0.21)
Enzymotec beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:34AM CST
ENZY: 8.00 (+0.21)
Enzymotec Ltd. Reports Third Quarter 2014 Unaudited Financial Results
GlobeNewswire - Thu Nov 13, 6:30AM CST
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today reported its financial results for the third quarter ended September 30, 2014.
ENZY: 8.00 (+0.21)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:30PM CST
KSS: 57.27 (+0.37), VTNR: 3.21 (-0.03), TYC: 41.55 (-0.63), SPH: 42.55 (-0.91), FLY: 13.20 (-0.61), ENZY: 8.00 (+0.21), RWLK: 21.22 (-0.28), WMT: 83.81 (-0.02), RSTI: 29.03 (-0.57), SBH: 30.85 (-0.27), HP: 60.34 (-1.33), GIB: 34.92 (-0.88), TDG: 192.06 (-1.08), CLFD: 11.92 (+0.21), HIMX: 7.97 (-0.02), VIAB: 72.96 (-0.01), MMS: 51.28 (-0.80)
Enzymotec Ltd. Initiates Clinical Study of Vayarin(R) in Adult ADHD
GlobeNewswire - Tue Nov 11, 7:38AM CST
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer, and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, today announced the initiation of a clinical study to evaluate the efficacy of Vayarin(R) in adults with Attention Deficit Hyperactivity Disorder, or ADHD.
ENZY: 8.00 (+0.21)
Enzymotec to Report Third Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Thu Oct 30, 7:30AM CDT
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today announced that the Company will release financial results for the third quarter ended September 30, 2014 on Thursday, November 13, 2014, before the market opens. Following the release, Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer will host a conference call to review the financial results.
ENZY: 8.00 (+0.21)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Involving Enzymotec Ltd. and a Lead Plaintiff Deadline of November 4, 2014 -- ENZY
GlobeNewswire - Wed Oct 29, 11:17AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Enzymotec Ltd. ("Enzymotec" or the "Company"
(Nasdaq:ENZY) common stock pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or investors who purchased shares on the open market between September 27, 2013 and August 4, 2014. ENZY: 8.00 (+0.21)
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Enzymotec Ltd.
Business Wire - Wed Oct 29, 9:30AM CDT
Glancy Binkow & Goldberg LLP reminds investors of Enzymotec Ltd. ("Enzymotec" or the "Company"
(NASDAQ:ENZY) that all purchasers of the Company's securities pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period" , have until November 4, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. ENZY: 8.00 (+0.21)
NOV. 4th DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Enzymotec Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of November 4, 2014
Business Wire - Mon Oct 27, 2:45PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Enzymotec Ltd. ("Enzymotec" or the "Company"
(Nasdaq:ENZY) common stock pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or investors who purchased shares on the open market between September 27, 2013 and August 4, 2014. ENZY: 8.00 (+0.21)
Which Stocks Hurt Billionaire Portfolios the Most in 2014?
at The Street - Mon Oct 27, 7:48AM CDT
See the stocks that have performed the worst for 19 billionaires who made their money investing.
BID: 38.82 (+0.06), CBI: 39.14 (-1.17), MDR: 2.46 (-0.17), DLIA: 0.01 (unch), EOPN: 7.57 (-0.11), PGEM: 12.18 (-0.35), ENZY: 8.00 (+0.21), GNC: 42.58 (-0.03), AMCC: 5.87 (+0.03), HHC: 127.30 (-3.11), LL: 58.88 (-0.35), VLTC: 0.82 (-0.07), CZR: 12.83 (-2.03), SNSS: 2.26 (unch), TWER: 1.62 (+0.05), SHOS: 12.00 (-0.04), DRYS: 0.86 (-0.05), CREE: 30.16 (-0.17)
ENZYMOTEC SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Enzymotec Ltd. -- ENZY
GlobeNewswire - Sat Oct 25, 4:49PM CDT
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 4, 2014 to file lead plaintiff applications in a securities class action lawsuit against Enzymotec Ltd. (Nasdaq:ENZY), if they purchased the Company's securities in connection with the Company's initial public offering ("IPO" on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period" . This action is pending in the United States District Court for the District of New Jersey. ENZY: 8.00 (+0.21)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Enzymotec Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of November 4, 2014
Business Wire - Tue Oct 21, 11:52AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Enzymotec Ltd. ("Enzymotec" or the "Company"
(Nasdaq:ENZY) common stock pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or investors who purchased shares on the open market between September 27, 2013 and August 4, 2014. ENZY: 8.00 (+0.21)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against Enzymotec Ltd.
Business Wire - Thu Oct 16, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that purchasers of the securities of Enzymotec Ltd. ("Enzymotec" or the "Company"
(NASDAQ:ENZY) pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period" , have until November 4, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. ENZY: 8.00 (+0.21)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Enzymotec Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of November 4, 2014 -- ENZY
PR Newswire - Mon Oct 06, 1:33PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Enzymotec Ltd. ("Enzymotec" or the "Company"
(Nasdaq: ENZY) common stock pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or investors who purchased shares on the open market between September 27, 2013 and August 4, 2014. ENZY: 8.00 (+0.21)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Enzymotec Ltd. to Contact Brower Piven Before the November 4, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- ENZY
GlobeNewswire - Sat Oct 04, 7:00AM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Enzymotec Ltd. ("Enzymotec" or the "Company"
(Nasdaq:ENZY) securities pursuant and/or traceable to the Company's Registration Statement and Prospectus ("Offering Documents" issued in connection with the Company's initial public offering on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period" . ENZY: 8.00 (+0.21)
ENZYMOTEC SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Enzymotec Ltd.
Business Wire - Fri Oct 03, 5:22PM CDT
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 4, 2014 to file lead plaintiff applications in a securities class action lawsuit against Enzymotec Ltd. (Nasdaq: ENZY), if they purchased the Company's securities in connection with the Company's initial public offering ("IPO" on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period" . This action is pending in the United States District Court for the District of New Jersey. ENZY: 8.00 (+0.21)
EQUITY ALERT: The Rosen Law Firm Reminds Enzymotec Ltd. Investors of Important Class Action Deadline -- ENZY
GlobeNewswire - Thu Oct 02, 1:13PM CDT
The Rosen Law Firm reminds purchasers of Enzymotec Ltd. securities (Nasdaq:ENZY) during the period from September 27, 2013 through August 4, 2014, of the important November 4, 2014 class action deadline.
ENZY: 8.00 (+0.21)
